Page 1138 - Hematology_ Basic Principles and Practice ( PDFDrive )

1004 Part VII Hematologic Malignancies

Crispino JD: GATA1 mutations in Down syndrome: implications for biology Tefferi A, Thiele J, Orazi A, et al: Proposals and rationale for revision of
and diagnosis of children with transient myeloproliferative disorder and the World Health Organization diagnostic criteria for polycythemia
acute megakaryoblastic leukemia. Pediatr Blood Cancer 44:40, 2005. vera, essential thrombocythemia, and primary myelofibrosis: recom-
Gamis AS, Alonzo TA, Gerbing RB, et al: Natural history of transient mendations from an ad hoc international expert panel. Blood 110:1092,
myeloproliferative disorder clinically diagnosed in Down syndrome 2007.
neonates: a report from the Children’s Oncology Group Study A2971. Tefferi A, Vainchanker W: Myeloproliferative neoplasms: molecular patho-
Blood 118:6752, 2011. physiology, essential clinical understanding and treatment strategies.
Gamis AS, Smith FO: Transient myeloproliferative disorder in children J Clin Oncol 29:573, 2011.
with Down syndrome: clarity to this enigmatic disorder. Br J Haematol Webb DK, Passmore SJ, Hann IM, et al: Results of treatment of children
159:277, 2012. with refractory anaemia with excess blasts (RAEB) and RAEB in trans-
Glaubach T, Robinson LJ, Corey SJ: Pediatric myelodysplastic syndromes: formation (RAEBt) in Great Britain 1990-99. Br J Haematol 117:33,
they do exist! J Pediatr Hematol Oncol 36:1, 2014. 2002.
Hasle H, Niemeyer CM: Advances in the prognostication and management Wlodarski MW, Hirabayashi S, Pastor V, et al: Prevalence, clinical charac-
of advanced MDS in children. Br J Haematol 154:185, 2011. terisitcs and prognosis of GATA2-related myelodysplastic syndromes in
Hasle H, Niemeyer CM, Chessells JM, et al: A pediatric approach to the children and adolescents. Blood 127:1387, 2016.
WHO classification of myelodysplastic and myeloproliferative diseases. Woodard P, Carpentaer PA, Davies SM, et al: Unrelated donor bone marrow
Leukemia 17:277, 2003. transplantation for myelodysplastic syndrome in children. Biol Blood
Loh ML: Recent advances in the pathogenesis and treatment of juvenile Marrow Transplant 17:723, 2011.
myeolomonocytic leukemia. Br J Haematol 152:677, 2011. Woods WG, Barnard DR, Alonzo TA, et al: Prospective study of 90 children
Maloney KW, Taub JW, Ravindranath Y, et al: Down syndrome preluekemia requiring treatment for juvenile myelomonocytic leukemia or myelodys-
and leukemia. Pediatr Clin North Am 62:121, 2015. plastic syndrome: a report from the Children’s Cancer Group. J Clin
Niemeyer C, Kang M, Shin D, et al: Germline CBL mutations cause Oncol 20:434, 2002.
developmental abnormalities and predispose to juvenile myelomonocytic Yoshida K, Toki T, Okuno Y, et al: The landscape of somatic mutations in
leukemia. Nat Genet 42:794, 2010. Down syndrome-related disorders. Nat Genet 45:1293, 2013.
Strahm B, Nollke P, Zecca M, et al: Hematopoietic stem cell transplanta-
tion for advanced myelodysplastic syndrome in children: results of the
EWOG-MDS 98 study. Leukemia 25:455, 2011. REFERENCES
Tefferi A, Gilliland DG: Oncogenes in myeloproliferative disorders. Cell
Cycle 6:550, 2007. For the complete list of references, log on to www.expertconsult.com.